论文部分内容阅读
特异性免疫治疗(SIT)作为目前唯一可能根治变应性疾病的治疗方法,不仅可以减轻过敏症状,减少用药,还可阻止自然病程的进展,预防新变应原的产生。近年来舌下SIT因其良好的安全性、有效性和易操作性已在欧洲各国广泛开展。标准化的变应原制剂在国内外逐步应用,已取代非标准化制剂。然而无论是皮下注射还是舌下含服方法,其具体有效剂量、治疗方案、治疗疗程尚待规范统一。随着对其作用机制的不断深入研究,以及以重组变应原为主的新制剂的研发,SIT的应用范围将会进一步扩大,更好地用于变应性疾病的治疗。
Specific immunotherapy (SIT) as the only possible cure for allergic diseases, not only alleviates the symptoms of allergies, reduce medication, but also to prevent the progression of the natural course of prevention of new allergens. In recent years, sublingual SIT has been extensively implemented in various European countries because of its good safety, effectiveness and ease of operation. Standardized allergen preparations are gradually applied both at home and abroad and have replaced non-standard preparations. However, whether subcutaneous injection or sublingual method, the specific effective dose, treatment options, treatment regimens yet to be standardized and unified. With the continuous research on its mechanism of action and the development of new preparations based on recombinant allergens, the scope of application of SIT will be further expanded and better used for the treatment of allergic diseases.